Summary
Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society. Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide. Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control. Thus, they cannot fully prevent T1D’s long term and acute side effects.
Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.
Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies.
The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.
LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.
Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.
Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies.
The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.
LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/837515 |
| Start date: | 01-12-2018 |
| End date: | 31-05-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society. Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide. Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control. Thus, they cannot fully prevent T1D’s long term and acute side effects.Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.
Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies.
The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.
LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
